Trial Profile
A multi-center, double-blind, placebo-controlled, randomized, multiple dose, 2-period cross-over, Phase IIa study to investigate the pharmacodynamics, tolerability and safety, and pharmacokinetics of ACT 129968 in subjects with mild to moderate allergic asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Sep 2015
Price :
$35
*
At a glance
- Drugs Setipiprant (Primary)
- Indications Allergic asthma
- Focus Pharmacodynamics
- Sponsors Actelion Pharmaceuticals
- 23 May 2012 Results presented at the 108th International Conference of the American Thoracic Society.
- 06 Jul 2011 New trial record